Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis.

Conclusion: In this real-world subgroup analysis of Korean patients in the ASTRIS study, osimertinib demonstrated comparable clinical efficacy to that attained in the global ASTRIS study and other clinical trials, with no new safety concerns.
PMID: 31581843 [PubMed - as supplied by publisher]

Source: Current Medical Research and Opinion - October 6, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research